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Immune protection against infectious diseases is most effective if located at the portal of entry of the pathogen. Hence, there is
an increasing demand for vaccine formulations that can induce strong protective immunity following oral, respiratory, or genital
tract administration. At present, only few mucosal vaccines are found on the market, but recent technological advancements and
a better understanding of the principles that govern priming of mucosal immune responses have contributed to a more optimistic
view on the future of mucosal vaccines. Compared to live attenuated vaccines, subcomponent vaccines, most often protein-based,
are considered safer, more stable, and less complicated to manufacture, but they require the addition of nontoxic and clinically safe
adjuvants to be effective. In addition, another limiting factor is the large antigen dose that usually is required for mucosal vaccines.
Therefore, the combination ofmucosal adjuvants with the recent progress in nanoparticle technology provides an attractive solution
to these problems. In particular, the liposome technology is ideal for combining protein antigen and adjuvant into an effective
mucosal vaccine. Here, we describe and discuss recent progress in nanoparticle formulations using various types of liposomes that
convey strong promise for the successful development of the next generation of mucosal vaccines.
1. Introduction
Most pathogens enter the body through mucosal surfaces
and, therefore, vaccines that target the respiratory, gastroin-
testinal, or urogenital tracts are attractive as they stimulate
local protection against infections. However, because of
the requirements for strong mucosal adjuvants and usually
relatively large amounts of antigen, only few such vaccines
have been developed and most of these are live atten-
uated vaccines. Whereas live attenuated vaccines can be
effective, subcomponent vaccines are usually safer and with
less manufacturing and regulatory complications. There-
fore, efforts are focused on developing mucosal vaccines
based on subcomponents, but this also requires identifying
appropriate and effective mucosal adjuvants to enhance the
immune response. Subcomponent vaccines can consist of
bacterial whole cell components, virus-like particles or other
particles, polysaccharides, complete protein structures, or
peptides that delivered at mucosal membranes together with
an adjuvant can stimulate strong immune responses and
protection against infection. Suchmucosal vaccines aremuch
warranted, as they carry several advantages over injectable
vaccines. In particular, mucosal vaccines can elicit both local
and systemic immune responses and they are safer as they
do not require needles and may allow for mass vaccina-
tion, when pandemic spread of infection is a threat [1, 2].
Mucosal vaccination could also lead to increased compliance
and reduce the risk of spreading transmissible diseases, as
has been experienced with spread of hepatitis C and HIV
infections following the use of injectable vaccines [3]. Most
importantly, mucosal immunization elicits antigen-specific
local IgA and systemic IgG antibodies, as well as strong
systemic and tissue resident CD4+ and CD8+ T cell immu-
nity (Figure 1). Despite these advantages, only few mucosal
vaccines are commercially available. The reason for this is
the need for safe and effective mucosal adjuvants and the
fact that many vaccine formulations require protection from
degradation of the antigens as seen, for example, after oral
administration [4]. Consequently, the development of novel
combinations of antigen and adjuvant into nanoparticles for
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Figure 1: Principles for induction of mucosal immune responses after intranasal vaccination. The respiratory mucosal immune system
consists of clusters of lymphoid cells beneath the mucosal epithelium, hosting both innate and adaptive immune cells [29]. There is a clear
distinction between inductive and effector sites and these are also physically separated. Inductive sites are organized lymphoid tissues where
antigen is taken up by DCs and other APCs. The effector sites, on the other hand, are tissues that provide protection against infection where
specific antibodies and CD4+ and CD8+ effector and memory T cells reside [30]. The main inductive sites for mucosal immune responses
after intranasal vaccination are known as nasopharynx-associated lymphoid tissue (NALT), which harbors B cell follicles and T cell zones in
well demarked microanatomical areas [31]. Antigens are taken up by DCs that get access to the luminal content either through direct uptake
through the epitheliumor via the follicle associated epithelium (FAE) that overlay theNALT. After antigen uptake, the immatureDCs undergo
maturation and subsequently leave themucosal tissue for the draining lymph nodes, alternatively, if already in the NALT, the DCs will directly
prime naive CD4+ or CD8+ T cells. Activated CD4+ T cells differentiate into various subsets: T helper 1 (Th1),Th2, orTh17 cells, regulatory T
cells (Tregs), or follicular helper T cells (TFH). The latter are critically needed for the expansion and differentiation of the activated B cells in
the germinal center (GC), which is formed in the B cell follicle in the lymph node after vaccination. TFH cells are involved in the development
of long-lived plasma cells and memory B cells in the GC.
the next generation of effective mucosal vaccines is much
needed.
Liposomes have been extensively used as delivery vehi-
cles for vaccine antigens; some of the advantages of these
formulations are (a) protection against antigen degradation,
(b) tissue depot effects or slow release of antigen, and (c)
facilitated uptake of antigen by antigen presenting cells (APC)
[5, 6]. Phosphatidylcholines are the most common lipids
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employed for liposome manufacturing. However, nanoparti-
cles can be developed fromawide range of lipids andproteins,
which have been found to also alter their physicochemical
and biological properties. Classical liposomes are now also
gradually being replaced by more advanced technologies
with the new generation of lipid-based nanovesicles (L-NVs),
which have more elaborate functions and less weaknesses.
Niosomes, transfersomes, sphingosomes, and other nonli-
posomal lipid-based nanoparticles are excellently reviewed
by Grimaldi et al. [7]. For example, the virus-like particle
(VLP) or virosome L-NV incorporates virus-derived or
recombinant proteins that in this way are effectively delivered
to the immune system [8]. This technology is used in two
commercial vaccines, Inflexal (against influenza) and Epaxal
(against hepatitis A) [9, 10]. Currently, several liposome-
based vaccine delivery systems against infectious diseases are
undergoing clinical testing (Table 1).
Mucosal vaccines were initially designed to be adminis-
tered orally. Later, also intranasal vaccines were developed
and today several different routes of administration are being
explored formucosal vaccination, including pulmonary, gen-
ital tract, rectal, and sublingual routes. Whereas preclinical
examples in animal models have shown that in principle
all of these routes work well, only the oral and intranasal
routes have been used for licensed human vaccines [11]. The
reason for this may simply be attributed to that a majority of
these vaccines are against gastroenteric infections (requiring
oral vaccines). Importantly, the adjuvant choice is critical
because it enhances and modulates the immune response to
the vaccine. For example, the breadth, the quality, and the
long-term protective effect of the vaccine may be directly
dependent on the adjuvant [12]. Liposomes can also function
as adjuvants in their own right, as they have been shown to
enhance immune responses even after oral administration
[13]. A particular type of liposomes, that is, layersomes,
which are liposomes coated with single or multiple layers of
biocompatible polyelectrolytes, has been found to stimulate
significant serum IgG and mucosal IgA antibodies and T
cell responses producing IL-2 and IFN-𝛾 [14]. Noteworthy,
though, the oral route most often requires high amounts
of antigen and protection against enzymatic degradation.
Moreover, an effective oral liposome vaccine should be
effective at breaching the mucus barrier to facilitate uptake
of antigen by gut mucosal antigen presenting cells (APCs).
Whereas oral vaccination provides a real challenge to
vaccine developers, the intranasal (i.n.) route is more permis-
sive. In fact, i.n. vaccination has several advantages compared
to oral vaccination. These include the need for less antigen
and a substantially reduced risk of antigen degradation
[15]. Interestingly, IgG-coupled liposomes with an enhanced
transmucosal transport were more immunogenic than plain
liposomes given i.n. [16]. Because of the compartmentaliza-
tion of the mucosal immune response, due to the acquisition
of tissue-specific homing receptors on activated lymphocytes,
nasal immunization also promotes a much stronger specific
immune response in the respiratory tract compared to oral
immunization. This also results in that excellent genital tract
immunity can be achieved after i.n, immunizations, while this
is not the case after oral vaccination.Thus, local secretory IgA
(sIgA) antibodies and genital tract cytotoxic T cells weremore
effectively stimulated after i.n. immunization than through
oral immunizations [17–20].
In this review we will describe and discuss liposomes as
vaccine delivery vehicles for efficient mucosal immunization.
In the first section, the impact of liposome composition and
structure for vaccine efficacy will be discussed and in the sec-
ond section the nature and qualities of the resulting immune
responses following liposome vaccination will be described.
Finally, in the last section, we have attempted to summarize
the current standing of the field of liposome-based vaccines
and future perspectives towards the development of the next
generation of effective mucosal vaccines.
2. Liposomes as Vaccine Delivery Vehicles
Liposomes are spherical lipid bilayer structures with an
aqueous core ranging in size from tens of nanometers to
several micrometers in diameter. Liposome technology was
first explored in the 1960s by Bangham et al. as a model
system for diffusion of ions across biological membranes,
and already in the 1970s there was an interest in using them
for drug delivery [39, 40]. At that time, some researchers
also tested them for adjuvant functions and ever since
they have been used in various vaccine formulations owing
to their inherent structural and chemical properties [41].
Phospholipids are most commonly the main constituents of
the shell that delimit the aqueous core of the liposome.These
molecules are amphiphilic and contain a hydrophobic tail
consisting of two fatty acids linked by a glycerol backbone
to a hydrophilic headgroup made up of phosphate and
potentially another organicmolecule that together determine
their chemical properties, as shown in Figure 2. In an aqueous
environment, this polarized structure facilitates self-assembly
into arrangements with the fatty acids facing each other
and forming an oil-like compartment between the outwards-
facing phosphate groups. In liposomes, the arrangement
is a hollow sphere, a vesicle consisting of either a single
or multiple phospholipid bilayers forming unilamellar or
multilamellar particles. Other types of lipids, all with the
amphiphilic structure in common, may be incorporated in
liposomes. Examples of other interesting lipid categories in
the context of vaccine carrier formulations are sterols, most
notably cholesterol (Chol); sphingolipids, with a sphingosine
backbone linked to a headgroup and a single acyl chain tail;
and fat-soluble vitamins such as tocopherols (vitamin E).
The fact that liposomes have both a hydrophobic and
a hydrophilic region makes them versatile and useful as
carriers for antigens: hydrophobic peptides or proteins can
be inserted into the inner hydrophobic center of the bilayer
while hydrophilic molecules can be either encapsulated in
the core of vesicles or bound to their surface (Figure 3(c)).
Surface binding of the antigen can be achieved by covalent
attachment or it can occur through adsorption or electrostatic
interactions. Alternatively, an antigen-bound hydrophobic
anchor can be inserted into the bilayer. Another advantage of
liposomes in vaccine formulations is that their physicochem-
ical properties are highly adaptable and their size, charge,
and lamellarity can be tailored to meet the requirements
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Table 1: Examples of liposome adjuvant vaccines against infectious diseases tested in clinical trials.This compilation of completed or ongoing
studies involving liposomes for vaccination of humans was generated with data from ClinicalTrials.gov. Here we have indicated the target
disease, the vaccine composition, the route of administration, the clinical testing stage, and the reference number.
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Table 1: Continued.
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of the vaccine. In particular, the charge and membrane
fluidity of the liposome can be fine-tuned by altering the lipid
composition [42].
The properties of different phospholipids depend on both
their polar headgroup and the nature of their fatty acid tails.
The characteristics of the lipid headgroup play a key role in
determining the surface properties and in particular the sur-
face charge of the vesicles. Naturally occurring phospholipids
can be categorized into 6 types according to their headgroup:
phosphatidylcholine (PC), phosphatidylethanolamine (PE),
phosphatidylserine (PS), phosphatidylinositol (PI), phos-
phatidylglycerol (PG), or phosphatidic acid (PA). Whereas
PS, PI, PG, and PA are negatively charged, PC and PE
are neutral but zwitterionic. Further, both the fluidity and
permeability of themembrane and, in extension, its resistance
to degradation, here referred to as stability, depend both on
the length and degree of saturation of the acyl chains of the
tail as well as the charge of the headgroup. All of these factors
influence the transition temperature of the lipid, which is in
turn decisive for whether the lipid membrane exists in gel-
or fluid-phase at a certain temperature. These factors also
determine the tendency of multicomponent membranes to
undergo small-scale phase separations resulting in heteroge-
neous distribution of different lipids. A common modulator
of the membrane permeability and fluidity is cholesterol,
which also influences the liquid-to-gel phase temperature
[43].
The possibility to chemically modify both the head-
group and the tail region gives rise to the option of pro-
ducing synthetic phospholipids tailored to specific require-
ments. For example, positively charged liposomes have been
made using synthetic cationic lipids, such as 1,2-dioleoyl-
3-trimethylammonium propane (DOTAP), 1,2-dimyristoyl-
trimethylammonium propane (DMTAP), and dimethyldioc-
tadecylammonium bromide (DDA). From this, it follows
that the choice of lipid composition will greatly impact the
biophysical and chemical properties of the liposome. Also,
by choosing lipids that naturally exist in cell membranes,
liposomes can be completely biodegradable, nontoxic, and
nonimmunogenic in themselves [44, 45]. On the other hand,
if components with an origin in archaeal, bacterial, or viral
membranes are chosen, they could enhance the immuno-
genicity of the formulation [35, 37, 46–50]. Accordingly, PS
is naturally exposed on the surface of cells undergoing
apoptosis, and in this way liposomes containing PSmay effec-
tively trigger phagocytosis by macrophages [51–53]. Finally,
many other modifications can be made to liposomes that
further extend the high versatility of these nanoparticles.
Suchmodification includes the attachment of targeting agents
such as galactose or APC-specific antibodies, of polymers,
for example, poly(ethyleneglycol), or the addition of different
kinds of coatings such as chitosan [38, 54–58]. Furthermore,
when introduced into a physiological fluid, nanoparticles
such as liposomes acquire a dynamic layer of adsorbed
proteins in a corona, the nature of which is determined by
both the particle’s size and surface properties as well as the
shear stress the particle is exposed to [59–62]. In practice
this means that carefully engineered surface properties may
be altered by the adsorption of a complex protein mixture.
This can have many diverse consequences; for example, the
protein corona may mask surface bound ligands and in this
way prevent receptor binding, or it can cause complement
activation [63–65].
3. Physiochemical Properties of
Liposomal Vaccines
3.1. Surface Charge. Although liposomes with different char-
acteristics have been extensively used for vaccine delivery,
it still remains to explain why the immune response is
modulated differently by different liposomal formulations. It
is inherently difficult to dissect the contribution of different
properties, as changing one property usually influences one
or several others. Surface charge can, for instance, be changed
by altering the lipid composition; however, by changing
the lipid composition also other properties might change,
such as membrane fluidity, rigidity, and stability. Hence, it
may be difficult to directly assess the influence of changing
different physicochemical properties of liposomes on the
immune response. Nevertheless, many attempts have been
made to describe the effects on immune responses after
altering liposomal characteristics. One of these parameters
is the charge of the liposome, which is assessed by the
zeta potential, a measure of the electrostatic potential at the
limit of what is called the diffuse electric double layer that
surrounds the particle (Figure 3(a)). The double layer is a
diffuse layer of differently charged ions spatially distributed
at the surface of the particle, which in this way becomes
shielded. The magnitude of the zeta potential, thus, depends
on the concentration of ions within the double layer, but
also other factors, such as the ionic strength and pH of
the dispersion medium. This must be kept in mind when
comparing zeta potential values reported in different studies
and under different conditions.
Because the cell surface as well as the mucus coating of
the mucosal membrane is negatively charged, it is frequently
hypothesized that positively charged liposomes will exhibit
stronger interactions with the cell membrane as well as
an increased mucoadhesion. The latter leads to reduced
clearance rate, that is, slower removal from themucosalmem-
branes. Noteworthy, both increased interactions with the cell
membrane and prolonged exposure time of the antigen at
the mucosal surface are thought to lead to increased cellular
6 Journal of Immunology Research
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...and combine them into custom liposomes!
...making up lipids with properties of your choice...
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Figure 2: Generation of customized liposomes. Lipids are polar molecules consisting of a hydrophilic headgroup and hydrophobic fatty acid
tails. Examples of positively charged headgroups are trimethylammonium propane (TAP) and dioctadecyl ammonium bromide (DA), while
negatively charged headgroups are phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylglycerol (PG), or phosphatidic acid (PA),
and finally neutral headgroups are phosphatidylcholine (PC) or phosphatidylethanolamine (PE). A headgroup can be combined with tails
of different nature to create lipids with the desired properties; the examples shown are the lipid 1,2-dioleoyl-3-trimethylammonium propane
(DOTAP) and the phospholipids dimyristoylphosphatidylglycerol (DMPG) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC).
Different lipids can then be combined into liposomes with different functional features, which provide the basis for this highly diverse and
versatile technology that is so excellently suited for vaccine development.



































Figure 3: Various properties of liposome-based vaccines. (a) The effect of altered surface charge on liposome function has been extensively
examined [32, 33]. (b)The lipid composition is critically influencing the immune response [34]. (c) Also the localization of the antigen on or
inside the liposome plays an important role in shaping the immune response to the vaccine. There are several modes of antigen association
to liposomes. Firstly, antigens may be encapsulated in the aqueous core or they could be linked to the surface via covalent attachment.
Alternatively, a hydrophobic anchor can be used to attach the antigen to the surface via adsorption or through electrostatic interactions
with lipids of opposite charge. For proteins with a hydrophobic region one may even successfully insert these in the liposomemembrane.The
liposomemay also be used as an immunoenhancer simply by admixing the antigen and the liposomes. (d)Only few studies have addressed the
impact of size or lamellarity [35, 36]. (e) Modifications of liposomes to increase their immunoenhancing effect can be done through attaching
PAMPs, such as lipid A (LPS), or through specific targeting strategies using cell-specific antibodies (anti-CD103 or -DEC205) [16, 37]. (f)
Other modifications, including addition of poly(ethylene glycol) (PEG) or different polymer coatings that increase the liposome penetration
of the mucosal barrier or to increase liposome resistance in biological fluids, have also been developed [38].
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uptake of antigen and stronger immune responses. However,
this may not always be the case. In general, positively cationic
charged liposomes have been shown to be better retained and
more immunogenic at mucosal membranes than negatively
charged or neutral liposomes [66, 67]. Furthermore, cationic
liposomes were found to effectively deliver antigen to both
mucus and antigen presenting cells (APCs) as shown in an in
vitro model of the airway epithelium with liposomes made
with distearoylphosphatidylcholine (DSPC)/trehalose 6,6-
dibehenate (TDB) (neutral) and DSPC/TDB/DDA (positive)
with varying amounts of DDA [68]. Moreover, cationic
liposomes consisting of DOTAP/Chol, DMTAP/Chol, or,
most prominently, the polycationic sphingolipid ceramide
carbamoyl-spermine (CCS) and cholesterol were shown to
effectively stimulate systemic and mucosal humoral and
cellular immune responses after i.n. immunizations in
mice [32]. By contrast, neutral liposomes with dimyris-
toylphosphatidylcholine (DMPC) or anionic liposomes with
DMPC/dimyristoylphosphatidylglycerol (DMPG)were com-
parably ineffective as immunogens [32]. While a positive
charge appears to increase the immunogenicity of liposomes,
it still remains to be investigated in greater detail. In fact,
negatively charged liposomes have been shown to be more
immunogenic than both zwitterionic and positively charged
liposomes and it has even been postulated that anionic lipo-
somes could exert an immunosuppressive effect on alveolar
macrophages and in this way promote an enhanced humoral
immune response [33, 69–72]. Hence, it can be hypothesized
that several mechanisms are modulated by the charge of
the liposome. It is also important to point out that altered
charge of the liposomes by necessity involves modifying the
lipid composition, which most likely will change also other
properties, such as membrane heterogeneity, fluidity, and
stability [73]. Naturally, also the charge of the liposome may
dramatically influence the immunogenicity when given by
different routes, as this may provide differentially charged
microenvironments.
3.2. Lipid Composition. The lipid composition (Figure 3(b))
is known to influence the stability of the liposome; a
more stable formulation might lead to a larger amount of
bioavailable antigen and potentially also a depot effect. Han
et al. made liposomes from various combinations of Chol,
dipalmitoylphosphatidylcholine (DPPC), dipalmitoylphos-
phatidylserine (DPPS), and distearoylphosphatidylcholine
(DSPC) and found that certain combinations impacted on
their stability. Liposomes with DSPC, having a higher tran-
sition temperature, were more stable in vitro and likely
protected antigen better from degradation in the gastroin-
testinal tract [49]. It was also found that stable lipo-
somes containing DPPS induced stronger IgA responses
compared to formulations without DPPS [34]. Combi-
nations of both DPPC/DMPG and DPPC/PS have been
found effective at targeting liposomes to macrophages,
though DPPC/DMPG were found more immunogenic than
liposomes with DPPC/palmitoyl phosphatidylethanolamine
(DPPE) orDPPC/PS. Noteworthy, changing the lipid compo-
sition also resulted in an altered charge, with the DMPG and
PS types being more negatively charged [73]. Furthermore,
cationic liposome-hyaluronic acid (HA) hybrid nanoparticle
systems have recently been developed and tested for DC
maturation. It was found that primarily an upregulation of
costimulatory molecules, including CD40, CD86, and MHC
class II, were responsible for an enhanced effect, which greatly
contributed to an enhanced specific T cell and antibody
response following i.n. vaccination [74].
As previouslymentioned, using archaeal lipids, liposomes
can be made more immunogenic and liposomes compris-
ing archaeal membrane lipids (archaeosomes) were found
considerably more potent than liposomes made with Egg
phosphatidylcholine (EPC)/Chol at inducing ovalbumin-
(OVA-) specific IgGand IgA antibodies following oral admin-
istration in a mouse model [46]. This was likely due to
increased stability in the gastrointestinal tract and to the fact
that the archaeosomes were better retained in the intestine
[46]. However, the difference may also partly reflect the
fact that the archaeosomes are negatively charged while the
EPC/Chol-liposomes are neutral.
3.3. Antigen Localization in Liposomal Formulations. There
are many ways of incorporating antigens into liposomes.
This raises the question of whether some strategies are
more effective than others in the context of optimizing the
immunogenicity of the liposome. Antigens can be hosted
in the aqueous core of the liposome, inserted into the
membrane leaflet or bound to the surface by covalent bonds
or intermolecular forces (Figure 3(c)). Hence, a plethora
of combinations exist and those could be used to enhance
resistance against antigen degradation or facilitate antigen
uptake. Thus, the liposome formulation may be tailored
for specific needs and purposes. If an oral vaccine is to
be designed, one may hypothesize that encapsulating the
antigen inside the liposomes should be an effective strat-
egy to prevent enzymatic degradation. However, by hiding
the antigen in the liposome, the immunogenicity may be
compromised because the antigen will not be immediately
accessible for APCs. Therefore, choosing how to physically
incorporate the antigen in the liposome may have critical
consequences and could dramatically change the immune
response. Unfortunately, until now such aspects have not
been addressed in a systematic manner. When administered
orally, encapsulated antigen may more effectively stimulate
local IgA and serum IgG antibody responses compared
to when soluble antigen is admixed with the liposomes
[73, 75]. On the other hand, following i.n. administration,
admixed antigen and liposome have been quite effective
even compared to liposome-encapsulated antigen [32, 70].
Interestingly, liposomes have been found to exert an immu-
noenhancing effect evenwhen administered 48 hours prior to
the antigen [70]. Furthermore, even liposome surface bound
antigens, rather than fully encapsulated antigens, have been
found to be more immunogenic following i.n. immunization
[71]. Probably, these observations underscore that the i.n
route is less sensitive to antigen degradation compared to the
oral route. Thus, depending on the route of administration,
it seems clear that antigens may or may not be immunogenic
when exposed on the surface of the liposome and for many
formulations it may, in fact, be advantageous to have surface
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bound as well as encapsulated antigens. Indeed, this may also
apply to the adjuvant. It was found that cholera toxin B-
subunit (CTB) adjuvant bound to the surface of the liposome
was more effective compared to when encapsulated in the
liposome [76]. In fact, a challenging question is what the
relationship and localization should be between the antigen
and the adjuvant in the liposome. Theoretically, it can be
argued that since the adjuvant is included primarily to
promote dendritic cells- (DC-) priming of the T cells it should
be encapsulated, while the antigen should be both encap-
sulated and surface bound to secure sufficient stimulation
also of naı̈ve B cells. Of note, B cells normally recognize 3D
structures with their receptors, while T cell receptors react to
degraded linear peptides. However, this interesting question
has been poorly investigated and only few studies have been
published on this topic. For example, it has been observed
that by altering the lipid-to-antigen ratio, the humoral and
cellular immune responses can be differentially induced [32,
77]. Thus, it is likely that the immune response following
liposome administration is susceptible not only to the choice
of antigen and lipid components but also to their relative
proportions and localization in the liposome.
3.4. Size and Lamellarity. A broad range of unilamellar and
multilamellar liposomes with varying sizes have been found
to have variable effects following mucosal immunization
(Figure 3(d)). While, unfortunately, the degree of multil-
amellarity is not routinely reported, the influence of size
and/or lamellarity on the immunogenicity of the liposome
is yet to be determined. For example, a comparative study
between unilamellar archaeosomes, 100 nm in diameter, or
large multilamellar aggregates of these clearly identified
better immunogenicity of the multilamellar aggregates [35].
Noteworthy, not only the size but also the lipid assembly
was different between the unilamellar and multilamellar
constructs, in this example. On the other hand, another
study reported that a “double liposome,” consisting of small
(∼250 nm) liposomes made from SoyPC, DPPC, Chol, and
SA encapsulated into a bigger (1 to 10𝜇m) outer liposome
made from DMPC and DMPG, was found only marginally
more immunogenic than the small liposomes given alone by
oral administration [36]. Taken together, constructing homo-
geneous monodisperse and unilamellar liposomes is highly
challenging and various degrees of multilamellar constructs
may coexist, making interpretations of experimental results
difficult, but recent advancements in this technology may
allow for more accurate comparisons of the influence of size,
lamellarity, and overall structure in the future [78].
3.5. Modifications Increasing the Bioavailability of Liposomal
Antigens. The microenvironment at mucosal surfaces often
promotes a high clearance rate of liposomes. Therefore,
various strategies have been tested to enhance mucus pen-
etration or to increase membrane adhesion to facilitate
bioavailability of the vaccine antigens (Figure 3(f)). Layer-
by-layer deposition of polyelectrolytes onto the liposome, for
example, has been used as a liposome-stabilizing approach
which resulted in higher specific IgA and IgG antibody levels
as well as an increased T cell response [79]. Polyvinyl alcohol
or chitosan has been tested to enhance bioadhesive properties
of the liposome and it has been observed that chitosan-
loaded liposomes, indeed, stimulated enhanced IgG antibody
responses [58]. Chitosan is a positively charged polysaccha-
ride that can form strong electrostatic interactions with cell
surfaces and mucus and, therefore, increase retention time
and facilitate interactions between the liposome and APCs
in the mucosal membrane. Alternatively, such modifications
can also transiently open tight junctions between epithelial
cells to allow for transmucosal transport of the liposomes
[80–82]. In fact, chitosan-coated liposomes have been shown
to give better serum IgG antibody levels compared to other
bioadhesive polymers, such as hyaluronic acid or carbopol
coated liposomes, and host much better immunogenicity
than uncoated negative, neutral, or positively charged lipo-
somes [38, 56–58].
Considerable attention has been given to studying how
liposomes are retained by and/or taken up across the
mucosal membranes. Liposome interactions with the intesti-
nal mucosa have been studied in vivo and ex vivo using
various in vitro models [46, 79, 83, 84]. The latter mod-
els have addressed whether passage of liposomes between
the tight junctions of epithelial cells can be achieved.
Indeed, tight junctions were reported to be open when
using PC/Chol-liposomes or Tremella-coated liposomes
[84]. Enhanced immune responses were also observed
with mucus-penetrating liposomes made with poly(ethylene
glycol) (PEG) or the PEG-copolymer pluronic [38]. Sig-
nificantly higher specific IgA and IgG antibody levels
were found with PEGylated than un-PEGylated liposomes.
Charge-shielding modifications with PEG or Pluronic F127
also proved useful in preventing liposome aggregation to
obtain small (<200 nm) chitosan-coated liposomes. In fact,
these shielded chitosan-coated and PEGylated liposomes
yielded the highest functional serum antibody titers of all
the formulations tested and the strongest IgA responses
[38].
3.6. Cell-Targeting Modifications of Liposomes. Modifica-
tions aimed at increasing liposome stability and/or uptake
have indeed proven effective. One of the most explored
modifications is aimed at targeting the delivery of lipo-
somes to subsets of cells. Liposomes can be equipped
with various targeting elements, aiming at enhancing their
immunogenicity (Figure 3(e)). For example, additional tar-
geting components may enhance the uptake by APCs or
the penetration of the liposome through the mucus layer.
The strongly GM1-ganglioside-binding molecule CTB has
been reported to enhance liposome immunogenicity. More-
over, when monophosphoryl lipid A, acting through the
TLR4 receptors, was added to liposomes their ability to
stimulate the innate immune response was dramatically
improved [34, 37, 49, 85, 86]. Other Toll-like receptor ago-
nists or Escherichia coli heat-labile toxin (LT) have also been
used in combination with liposomes as adjuvants [47, 87].
Furthermore, linking CpG, which acts through TLR9 sig-
naling, or Bordetella pertussis filamentous hemagglutinin to
the liposome has all been found to enhance immunogenicity
[88, 89].
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In fact,many different liposome cell-targeting approaches
have been investigated. To this end, specific antibodies have
been found to enhance binding to M cells, thereby targeting
the liposome to the follicle associated epithelium (FAE).
This is the thin epithelial cell layer that is responsible for
antigen uptake from the luminal side, such as the epithelium
that overlays Peyer’s patches (PP) in the small intestine [16].
Similarly, lectin Agglutinin I from Ulex europaeus coated
liposomes were shown to improve M cell-targeting and
antigen uptake [83, 90, 91]. Also, galactosylation of liposomes
resulted in higher specific IgA and IgG antibody levels
compared to unmodified liposomes [54]. Moreover, lipo-
somes coated with the influenza virus protein hemagglutinin
were more immunogenic than uncoated liposomes [50]. In
addition, mannosylated lipids or anti-CD40 antibody-coated
liposomes were found to host an enhanced ability to target
DCs and, thereby, greatly promoted a stronger immune
response [55, 87]. Furthermore, the identification of Mincle,
a receptor for the mycobacterial cord factor trehalose 6,6󸀠-
dimycolate (TDM), on innate immune cells, led to that TDM
analogs were found to be effective stimulants of the produc-
tion of G-CSF in macrophages. Indeed, immunizations in
mice with cationic liposomes containing the analogues TDM
demonstrated a superior adjuvant activity [92].
Many strategies have, indeed, been applied to achieve
cell-targeting of liposomes, with varying degrees of improved
function. Needless to say, there exist a plethora of possibilities
to explore when it comes to targeting liposomes to the cells of
the mucosal immune system. If analytical tools are combined
with suitable in vitro and in vivo assay systems it will
greatly help identifying the relative importance of liposome
targeting and how composition, such as size, lamellarity,
surface charge, and fluidity of the membrane, can influence
the immune response.
4. Mucosal Immune Responses to Liposomes
Prior to an adaptive immune response, innate immune
activation must have occurred, leading to the production
of proinflammatory molecules and the expression by APC
of costimulatory and immunomodulating molecules, that
is, chemokines, cytokines, and the costimulatory molecules
CD80, CD86, CD40, and others. Innate immune activators
can be classified into several categories, including the domi-
nant ones, Toll-like receptors (TLRs), C-type lectin receptors
(C-LRs), and non-Toll-like receptors (NLRs) [93, 94]. These
receptors recognize pathogen-associated molecular patterns
(PAMPs), such as bacterial cell-wall components (e.g., pepti-
doglycan, lipoteichoic acid, and flagellin) and different forms
of microbial nucleic acids (e.g., double-stranded RNA, high-
CpG-content DNA). The role of an adjuvant in a vaccine
formulation is, thus, to activate innate immunity and, there-
fore, most vaccine adjuvants are derived from PAMPs. Also
for mucosal vaccines it is critical to induce a sufficient and
appropriate innate immune response, preferentially, without
causing unwanted side effects, such as tissue damage. Thus, a
successful mucosal vaccine must be capable of inducing not
only an adaptive immune response, but also a strong innate
immune response [13]. Fortunately, liposomes can do both.
They can both serve as delivery vehicles for vaccine antigens
and act as immunomodulators, triggering both innate and
adaptive immune responses. Indeed, many modifications of
the liposome itself can dramatically influence the innate
immune response and, thereby, augment or qualitatively
modify also the adaptive immune response. To this end,
altered lipid composition, charge, particle size, or added
targeting elements can all be utilized to tailor the immune
response to the liposome and stimulate the required anti-
infectious immune response (Figure 3). In addition, to get an
even stronger activation of innate immunity, liposomes can
be equipped with specific adjuvants/PAMPs, such as flagellin
or CpG, as we have already discussed.
Mucosal immunizations as opposed to systemic immu-
nizations effectively support IgA class switch recombination
(CSR) and production of sIgA at mucosal sites [95]. In
the intestine, this occurs in the organized gut associated
lymphoid tissues (GALT) and, in particular, in Peyer’s patches
(PP), which are the dominant sites for IgA CSR in the gut.
In the upper respiratory tract the most active inductive site
is the nasal associated lymphoid tissues (NALT), but also
cervical lymphnodes and themediastinal lymphnode (mLN)
are central to the mucosal immune response. Ultimately,
targeting of the liposome to these sites could be a much
preferred strategy in future vaccine formulations, as already
discussed. Following antigen recognition and activation of
specific B cells inGALT andNALT, these cells undergo strong
expansion in the germinal centers (GC) in the B cell follicles.
Most immune responses are T cell dependent and, thus,
the expanding B cells require the participation of follicular
helper T cells (TFH) in the GC to differentiate into long-lived
plasma cells and memory B cells. These CD4+ T cells are
generated through the peptide-priming event that the DCs
orchestrate in the T cell zone in the lymph node. In this
way, the DC is a key player in the immune response and
it impacts also the ability of the activated lymphocytes to
migrate to the effector tissue from where the DC originated.
The plasma cells, thus, eventually migrate from the inductive
site via the lymph and blood back to the lamina propria in the
mucosal membrane, where they produce sIgA. Thus, there is
a complex series of events that need to be completed before a
productive sIgA response can be found in the lamina propria
of the mucosal membrane (Figure 1). Hence, liposomes can
be made to impact or modulate many different steps in this
series of events. A critical question is how we can assess and
compare different liposome formulations for their efficacy
and characteristic impact when multiple steps are involved.
We would advocate a reductionist approach where different
liposomes are evaluated for their effect in different stages of
the buildup of an immune response. Therefore, in the next
section we focus on the interaction of liposomes with DCs
and APCs in general.
4.1. Innate and Adaptive Immunity against Liposome Vac-
cination. Although significant progress has been made in
understanding antigen uptake and processing of liposome
delivered antigens, the fine details of these processes are
still poorly known. Liposomes that enhance cell membrane
fusion, that is, fusogenic liposomes, deliver their antigenic
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content to the cytoplasm of the APC, which enables MHC
class II presentation to CD4+ T cells and in some DC
subsets also allows for cross-presentation to MHC class I
restricted CD8+ T cells. Of note, liposomes that are taken
up via scavenger receptors (CD68, CD36, and Clec LOX-
1) or other innate immune receptors are usually restricted
to prime CD4+ T cells through MHC class II presentation.
Thus, targeting of liposomes to different DC subsets or
uptake mechanisms can provide a means to specifically tailor
the immune response to a certain antigen or facilitate the
development of a distinct type of immune response [96,
97]. For instance, whereas zwitterionic or anionic liposomes
have not been reported to drive inflammation, cationic
liposomes have been shown to stimulate proinflammatory
responses in DCs, leading to an upregulation of costimu-
latory molecules, CD80 and CD86, and proinflammatory
cytokines [98]. Furthermore, Yan et al. reported that DC
stimulation by cationic liposomes composed of DOTAP (1,2-
dioleoyl-3-trimethylammonium propane) also stimulated
reactive oxygen species (ROS), which activated extracellular
signal-regulated kinase (ERK) and p38, and downstream
proinflammatory cytokines/chemokines, interleukin-12 (IL-
12), and chemokine (C-C motif) ligand 2 (CCL2) [99]. In
addition, DOTAP liposomes were shown to induce tran-
scription of monocyte chemoattractant protein-1 (MCP-
1/CCL2), macrophage inflammatory protein-1 alpha (MIP-
1𝛼/CCL3), and macrophage inflammatory protein-1 beta
(MIP-1𝛽/CCL4) [100]. Also DiC14-amidine cationic lipo-
somes can induce the secretion of IL-1𝛽, IL-6, IL-12p40,
interferon-𝛽 (IFN-𝛽), interferon-𝛾-inducible protein 10 (IP-
10), and TNF-𝛼 by human and mouse myeloid DCs [101].
While anionic liposomes in general are poorly proinflam-
matory, modifications such as using mannosylated lipids
could make these liposomes much more proinflammatory
and effective at stimulating DCs [102, 103]. With regard to
macrophages it has been reported that galactose-modified
liposomes can stimulate TNF-𝛼 and IL-6 production, which
was associated with significantly higher specific sIgA anti-
body levels in the nasal and lung tissues and increased serum
IgG antibodies [54].
Carefully analyzing the literature, it appears unclear
how different liposomes stimulate strong innate immune
responses. A high density of positive charges on liposomes
is considered beneficial, while negatively charged or neutral
lipids are likely to lower this capacity [104, 105]. Asmentioned
previously, liposomes effectively stimulate both T and B
cell responses, but it is their direct impact on the DCs
that matters for the adaptive immune response. In fact, the
uptake of liposomes by DCs has an important effect on the
development of different CD4+ T cell subsets. These CD4+ T
cell subsets have both distinct and overlapping functions, but
their individual impact on the immune response is critical.
For example, if protection against a pathogen requires IFN-
𝛾 production (Th1 cells), then the development of exclusive
Th2-dominated responses can be detrimental. Therefore, in
this context, monophosphoryl lipid A (MPL) (a TLR4 ligand)
or monomycoloyl glycerol (MMG) combined with DDA in
a liposome will consistently promote IFN-𝛾 production, that
is, a Th1-biased immune response [106]. Moreover, trehalose
dibehenate (TDB) liposomes, together with the combined
Ag85B-ESAT-6 vaccine antigen, enhanced antituberculosis
specific IFN-𝛾 and IL-17 production, as well as increased
specific serum IgG2 antibody levels [107]. While the com-
position of lipids matters for the subset of CD4+ T cell
that the DC can prime, also a larger size of the liposome
may influence the generation of Th1 CD4+ T cells [108].
However, the mechanism for this effect is unclear but could
relate to the fact that different subsets of DCs or other APCs
like macrophages are involved in processing differently sized
liposomes, such that small sized liposomes preferentially
stimulate Th2 CD4+ T cell responses. On the other hand,
it has been claimed by many investigators that protection is
best achieved with a balanced Th1/Th2 response. Liposome-
based microneedle array (LiposoMAs) and a mannose-
PEG-cholesterol (MPC)/lipid A-liposome (MLLs) system are
both examples of liposome formulations with a balanced
Th1/Th2 response [109–111]. An even more complex vector is
the combination of nanoparticle technology and liposomes
with biodegradable poly(DL-lactic-co-glycolic acid) (PLGA),
cationic surfactant dimethyldioctadecylammonium (DDA)
bromide, and the immunopotentiator TDB which promotes
Th1 and Th17 CD4+ T cell responses and enhanced specific
serum antibodies [112]. Moreover, the mycobacterial cell-
wall lipid monomycoloyl glycerol analog has been used
in combination with DDA. This combination resulted in
a promising vaccine delivery system that induced strong
antigen-specific Th1 andTh17 responses [113].
Protection against most infections requires both anti-
bodies and adequate T cell immunity. However, for most
infectious diseases we have given strongest attention to anti-
bodies as correlates of protection.However, this scenariomay
change when we will identify more and more T cell mediated
parameters that correlate with protection. Recently, it was
identified that in influenza the best correlate of protection in
a study with healthy human volunteers was the preexisting
influenza-specific CD4+T cells [114]. It has been found that
high density antigen coating onto liposomes often stimulates
better antibody responses than encapsulated antigens, but a
combination, such as the DOTAP-PEG-mannose liposomes
(LP-Man), will enhance not only antibody responses but
also APC antigen uptake and strong memory CD4+ T cell
development [115–118]. This and other progress in the field
have to be considered when developing programs for the
evaluation of vaccine efficacy. For example, with liposome
vaccines as novel universal, broadly protective, influenza
vaccines against also heterosubtypic virus strains, it will be
important to also assess and evaluate CD4+ T cell immunity
as a correlate of protection. Therefore, we need to better
define how specific CD4+ T cells, and, for that matter CD8+
T cells, correlate to impaired viral replication or bacterial
growth and reduced transmission of infection.
5. Concluding Remarks and
Future Perspectives
Here, we have described and discussed recent progress
in nanoparticle formulations using liposomes for mucosal
12 Journal of Immunology Research
vaccine delivery against infectious diseases. We have under-
scored the complexity of the liposome formulation and
pointed to many combinations and plasticity of the liposome
nanoparticle as a carrier of vaccine antigens and adjuvants.
Needless to say, when considering liposome-based vaccines,
it is important to consider all the properties of the for-
mulation, the route of administration, and the biological
response.Thus, liposome size, lamellarity, and surface charge
as well as lipid composition and fluidity of the membrane
can all influence the immune response following vaccination.
Importantly, the choice of antigen, with its own inherent
physicochemical properties, and the position of the antigen
and the adjuvant in the liposome critically affect the function
of the liposome. The antigen/lipid ratio and properties of the
added adjuvant are also important parameters that change the
immunogenicity and stability of the liposome.
Most studies using liposome-based vaccines have focused
on the end result of immunization, namely, the magnitude
and the quality of the immune response. Few studies have
attempted to systematically identify mechanism of action at
the different stages of an immune response. For mucosal
immunizations liposome vaccines have been thoroughly
investigated for their stability in intestinal fluids, their
mucoadhesive properties, or the efficiency in targeting and
uptake by DCs and other APCs [46, 49, 58, 79, 119, 120].
The site of liposomal penetration of the mucosal barrier is
important to determine. If occurring at the duodenal site,
the outcome may be significantly different from penetration
that takes place in the ileum or colon of the gut. Similarly,
antigen uptake in the NALT may be more effective than if
the liposome reaches deeper into the respiratory tract. This
is not just because of the stability of the liposomal antigen at
a distinct location, but also theDC subsets that are exposed to
the antigen may differ dramatically and, hence, the outcome
of the vaccination may vary. At the cellular level, we largely
lack studies that investigate how liposome delivered antigens
are processed and presented byDCs, the kinetics of these pro-
cesses, and whether the formulation will affect the migration
and function of the DC in the draining lymph node. More
work is needed to generalize the principles for an optimal
design of the liposome in this regard. For example, it still
remains unclear whether liposomes that rapidly penetrate the
mucosal barrier are also good inducers of a mucosal immune
response or, alternatively, shouldmucoadhesive liposomes be
used to provide a depot of antigen for an extended loading
of DCs with antigen. Simple screening systems should be
developed to address these questions. To assess whether a
liposome efficiently delivers peptide for CD8+ or CD4+ T
cell priming, one could focus on surface expression on the
DC of complexes with MHC class I and II molecules plus
peptide using specific antibodies that detect these complexes
and flow cytometry analysis [121]. In this way, screening of
liposome-antigen formulations could be evaluated on the
basis of effective expression of such complexes on the surface
of a target DC population in vitro and in vivo. The density
of such complexes most likely will relate to the ability of the
DC to effectively prime the T cells in the lymph node as
the T cell receptor does not recognize the peptide, but the
complex.
Identifying and standardizing liposome-stimulated im-
mune responseswould greatly aid in the prospects of compar-
ing different liposome vaccine formulations for their efficacy.
This would also contribute to a more rational design of
effective liposome-based mucosal vaccines. Currently, there
is no agreed protocol or procedure on how to evaluate and
characterize the immune response to liposomes. Hence, most
studies are performed without relevant comparisons and the
evaluation of whether the liposome formulation is more or
less effective compared to other types of formulations is
impossible to assess. Therefore, it would be an advantage
if investigators could agree on using some standardization
protocol, perhaps using cholera toxin or some other strong
soluble adjuvant, to admix with antigen and compare the
immune response to those of the liposomes. Thus, it is fair
to say that we still lack comprehensive comparisons to other
modes of formulating antigens for mucosal vaccination.
The liposome technology applied to the development of
the next generation ofmucosal vaccines holdsmuch promise.
It is conceivable that better targeted liposomes with added
adjuvant capacity will prove to be effective in stimulating
mucosal immune responses that are protective against mul-
tiple infectious diseases. It is likely that these liposomes
have both surface anchored antigen and encapsulated antigen
to optimize B cell as well as T cell priming. The lipid
compositions that yield higher gel-liquid crystal transition
temperatures will be preferred as they have been found
to stimulate stronger immune responses. Cationic rather
than neutral liposomes, being more proinflammatory, will be
selected for mucosal immunization. It will be important in
the future to apply the better understanding of the liposome
manufacturing technology and the principles for induction of
mucosal immune responses to the design and development of
the next generation of mucosal vaccines.
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